Dupixent shows promise for eczema skin barrier in chinese patients

NCT ID NCT05624112

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug dupilumab (Dupixent) in 44 Chinese patients aged 12 to 65 with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug improves skin barrier function by measuring water loss through the skin over 16 weeks. Participants received dupilumab injections and had regular skin tests. The study is complete, but results are not yet published.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (Dupixent)
What this could lead to: If successful, this could confirm that dupilumab improves skin barrier function, supporting its use for managing atopic dermatitis.
What could go wrong: This is a small, open-label study with no placebo group, so results may not be definitive. It only looks at a specific measure (water loss) and may not reflect overall symptom improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS DERMATITIS ATOPIC

Contacts and locations

Locations

Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)

Guangzhou, Guangdong, 510091, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.